NON CLINICAL DEVELOPMENT OF DRUG SPECIALITIES ________________________ Bernard MARCHAND
description
Transcript of NON CLINICAL DEVELOPMENT OF DRUG SPECIALITIES ________________________ Bernard MARCHAND
![Page 1: NON CLINICAL DEVELOPMENT OF DRUG SPECIALITIES ________________________ Bernard MARCHAND](https://reader034.fdocuments.in/reader034/viewer/2022042617/56814a9a550346895db7aa04/html5/thumbnails/1.jpg)
NON CLINICAL DEVELOPMENT OF NON CLINICAL DEVELOPMENT OF DRUG SPECIALITIESDRUG SPECIALITIES
________________________________________________
Bernard MARCHANDBernard MARCHAND
![Page 2: NON CLINICAL DEVELOPMENT OF DRUG SPECIALITIES ________________________ Bernard MARCHAND](https://reader034.fdocuments.in/reader034/viewer/2022042617/56814a9a550346895db7aa04/html5/thumbnails/2.jpg)
ExploExplo
ProjecProjectt
Preclinical Preclinical Stage AStage A Phase IPhase I Phase Phase
IIII
Phase IIIPhase III NDANDAPost Post NDANDA
Preclinical Preclinical Stage BStage B
BioPharmaceutica
l Research
TOXICOADME
Salt Selection
Phase IFormulatio
n
PK Interaction
sPB/PK
PK/PD
Up scaled Formulatio
n
Toxicological and kinetics Expertises
PopulationKinetic
Interspecies
metabolismcomparison
Pharmaceutical File
NewFormulation
Pharmaceutical
Support Regulatory
AffairsPharmacopoe
iaCopy
Analysis
![Page 3: NON CLINICAL DEVELOPMENT OF DRUG SPECIALITIES ________________________ Bernard MARCHAND](https://reader034.fdocuments.in/reader034/viewer/2022042617/56814a9a550346895db7aa04/html5/thumbnails/3.jpg)
PharmacokineticPharmacokineticToxicologyToxicology
PhysicochemistryPhysicochemistryPreclinical Preclinical DevelopmentDevelopment
New targets New tools comingfrom development
RESEARCHPHARMACOLOGY
CHEMISTRY
StructureActivity
Relationships
BIOPHARMACEUTICALSCREENING
DEPARTMENT
Hits Identification
Lead Optimisation
Candidat Selection
Analytical methods, Absorption
Metabolic stabilitySolubility,Specific
questions...
![Page 4: NON CLINICAL DEVELOPMENT OF DRUG SPECIALITIES ________________________ Bernard MARCHAND](https://reader034.fdocuments.in/reader034/viewer/2022042617/56814a9a550346895db7aa04/html5/thumbnails/4.jpg)
HTS SDS Preclinical Development
ClinicalTrial
1 drug1- 3 drugs30 - 3 drugs300 - 30 drugs
Lead Optimisation Back-up
Intestinal absorption P450 Isoenzymes Metabolic Stability Inhibition Metabolic pathway Induction Other parameters BBB permeation/Cell toxicity
DISCOVERY PROCESS & BIOPHARMACY DESCRIPTORS
![Page 5: NON CLINICAL DEVELOPMENT OF DRUG SPECIALITIES ________________________ Bernard MARCHAND](https://reader034.fdocuments.in/reader034/viewer/2022042617/56814a9a550346895db7aa04/html5/thumbnails/5.jpg)
MAJOR TECHNICAL EVOLUTIONS IN BIOPHARMACY
* ** ** * * * * * * * * * * * * * * * **HPLC
LC/MS/MS
ANALYTICAL
DETECTION
SAMPLE PREPARATION
CELLLULAR MODELS(Caco2, hepatocytes)
GENETIC TOOLS(Human DNA)
Automation (96 wells)
SUBCELLULARMODELS
Hepatic Microsomes(animal +
man)
BIO INFORMATIC
Data Analysis Modelisation
Cassette Dosing
![Page 6: NON CLINICAL DEVELOPMENT OF DRUG SPECIALITIES ________________________ Bernard MARCHAND](https://reader034.fdocuments.in/reader034/viewer/2022042617/56814a9a550346895db7aa04/html5/thumbnails/6.jpg)
ABSORBED FRACTION
SOLUBILITY
Fraction of the dosesolubilised
in the intestin
ABSORBEDFRACTION
PERMEABILITY SOLUBILITY
LIPOPHILY
PERMEABILITY
Molecular WeightNitrogenOxygene
Hydrogen BondsIonisation
![Page 7: NON CLINICAL DEVELOPMENT OF DRUG SPECIALITIES ________________________ Bernard MARCHAND](https://reader034.fdocuments.in/reader034/viewer/2022042617/56814a9a550346895db7aa04/html5/thumbnails/7.jpg)
Caco2 PERMEABILITY MODEL
Different Transport Mechanisms
- Transcellular (passive)(lipophilic)
- Paracellular (passive)(hydrophilic)
- Transcellular (active) (transportors)- Efflux Process
(PGP)
HUMAN ENTEROCYTE CELLS
![Page 8: NON CLINICAL DEVELOPMENT OF DRUG SPECIALITIES ________________________ Bernard MARCHAND](https://reader034.fdocuments.in/reader034/viewer/2022042617/56814a9a550346895db7aa04/html5/thumbnails/8.jpg)
Intestin
Liver
GeneralCirculation
HEPATIC BARRIER
Metabolism RateComponent of theterminal half time
Metabolic Bioavailability (first pass effect)Metabolism
rapidity
LIPOPHILY
![Page 9: NON CLINICAL DEVELOPMENT OF DRUG SPECIALITIES ________________________ Bernard MARCHAND](https://reader034.fdocuments.in/reader034/viewer/2022042617/56814a9a550346895db7aa04/html5/thumbnails/9.jpg)
PREDICTION OF IN VIVO METABOLIC BIOAVAILABILITY
Km vitro
Vm vitro
Km vivo
Vm vivo
g prot/g liver and g liver/animal
MetabolicBiovailability
Q*fu*Vm*S/(Km+S) BloodFlow
Q+fu*Vm*S/(Km+S)
PlasmaProteins
Concentration IN
ConcentrationOUT
MetabolitesConcentration
Ka Dose
![Page 10: NON CLINICAL DEVELOPMENT OF DRUG SPECIALITIES ________________________ Bernard MARCHAND](https://reader034.fdocuments.in/reader034/viewer/2022042617/56814a9a550346895db7aa04/html5/thumbnails/10.jpg)
SIMULATION IN RELATION TO DOSE
predicted clinical doses
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
0,01
0,08
0,64
5,12
40,9
6
327,
68
2621
,44
SimLin
Dose (mg/kg)
DOG
+++
MAN
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
0,01
0,08
0,64
5,12
40,9
6
327,
68
2621
,44
SimLin
Dose (mg/kg)
+
RATRAT
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
0,01
0,08
0,64
5,12
40,9
6
327,
68
2621
,44
2097
1,52
SimLin
Dose (mg/kg)
+ ++
Met
abol
ic B
ioav
aila
bilit
y
Bio
disp
onib
ilité
mét
abol
ique
Bio
disp
onib
ilité
mét
abol
ique
In vivo/In vitrocorrelation in one species :Mixture of products (cassette dosing 5/Rat - 50/Dog
![Page 11: NON CLINICAL DEVELOPMENT OF DRUG SPECIALITIES ________________________ Bernard MARCHAND](https://reader034.fdocuments.in/reader034/viewer/2022042617/56814a9a550346895db7aa04/html5/thumbnails/11.jpg)
1A26%
2A62%
2C910%
2C194%
2D630%
2E15%
3A443%
NATURE AND NUMBER OF INVOLVED P450
Interest in screening :- Avoid one polymorphic enzyme- Avoid metabolism by only one P450
MetabolicStability
± specific inhibitors
![Page 12: NON CLINICAL DEVELOPMENT OF DRUG SPECIALITIES ________________________ Bernard MARCHAND](https://reader034.fdocuments.in/reader034/viewer/2022042617/56814a9a550346895db7aa04/html5/thumbnails/12.jpg)
Enterocyte humain : transport et métabolisme
UGTUGT 1A61A6 3A43A4 UGTUGT 2B22B277 3A43A4
hOATP-B(?)
MRP-3
MRP-1
MRP-(5?)
BCRP
ISBT
LRP
MRP-1(?)MRP-
2P-gp (MDR-1)
PepT1ASBT
Na+/SLGT1
SPNT1Dipeptide
TripeptideTransporters
MCT(drug/H+co-transporter)
SANG
VEINE
PORTE
I
N
T
E
S
T
I
N
Noyau 1A1A113A3A441A1A22
Jonctions Jonctions serréesserrées
Jonctions serréesJonctions serrées
![Page 13: NON CLINICAL DEVELOPMENT OF DRUG SPECIALITIES ________________________ Bernard MARCHAND](https://reader034.fdocuments.in/reader034/viewer/2022042617/56814a9a550346895db7aa04/html5/thumbnails/13.jpg)
BLOOD BRAIN BARRIER MODELE
Transport Study(filter +/- cells)
Astrocytes(confluent in 3
weeks)Ringer HEPES
Drug
6 wales plates
BBCE (confluent and differenciatedin 1 week and
ready to use for 5 days)
Basolateral
ApicalLC-MS-MS
Quantitation(10, 15, 20, 30, 45
min)
Co-culture of Bovin Brain Capillary Endothelial Cellswith rat astrocytes (Pr Ceccheli - Lille)
![Page 14: NON CLINICAL DEVELOPMENT OF DRUG SPECIALITIES ________________________ Bernard MARCHAND](https://reader034.fdocuments.in/reader034/viewer/2022042617/56814a9a550346895db7aa04/html5/thumbnails/14.jpg)
CORRELATION Caco2/BHE
-13
-12
-11
-10
-9
-8
-7
-6
-10 -9 -8 -7 -6 -5 -4
Log Papp BBB
Log
Papp
Cac
o2
Mannitol
Terbutaline Pipenzepine
Sucrose Urée
DopamineAc Acetylsalicylique
NicotineDexamethazonePindolol
HydrocortisonePropanolol
CafeinePhenytoinDiazepamR = 0.74
![Page 15: NON CLINICAL DEVELOPMENT OF DRUG SPECIALITIES ________________________ Bernard MARCHAND](https://reader034.fdocuments.in/reader034/viewer/2022042617/56814a9a550346895db7aa04/html5/thumbnails/15.jpg)
SCREENING IN TOXICOLOGY
MutagenesiMutagenesissAmes II
Automatised Micronucleus ?
Morphology, Viability, Glutathion level
Cellular Toxicology with cryopreserved Cellular Toxicology with cryopreserved hepatocytes ? hepatocytes ?
In vitro model answering in vivo issues In vitro model answering in vivo issues Ex : vacuolisation on cultured fibroblastes
Toxicogenomics ?Toxicogenomics ?
![Page 16: NON CLINICAL DEVELOPMENT OF DRUG SPECIALITIES ________________________ Bernard MARCHAND](https://reader034.fdocuments.in/reader034/viewer/2022042617/56814a9a550346895db7aa04/html5/thumbnails/16.jpg)
Global approach
Significant geneinduction or repression
Cells / Tissues RNA Hybridization
Database mining and mecanistic interpretation
Image analysis
TOXICOGENOMICS
![Page 17: NON CLINICAL DEVELOPMENT OF DRUG SPECIALITIES ________________________ Bernard MARCHAND](https://reader034.fdocuments.in/reader034/viewer/2022042617/56814a9a550346895db7aa04/html5/thumbnails/17.jpg)
maxmin
Control Phenobarbital
CYP2BCYP3A
RESULTS
![Page 18: NON CLINICAL DEVELOPMENT OF DRUG SPECIALITIES ________________________ Bernard MARCHAND](https://reader034.fdocuments.in/reader034/viewer/2022042617/56814a9a550346895db7aa04/html5/thumbnails/18.jpg)
Gene Category Selected Genes
•Apoptosis•Cell cycle•DNA damage/Repair•Inflammation•Oncogene•Stress response•Peroxisome Proliferators •Transcription factors, growth factors•Plasma transport•Phase I•Phase II•Phase 0/III•CYPs regulating nuclear factors
•Bax, Bcl-2, Bcl-X, c-myc, c-fos, caspase 7-8,CD 27, TNF, Smp30•Cyclin A-B1- D1/2/3-E1, cdK 2-4-6,JNK-1, Telomerase•GADD45, GADD153, MGMT, p16, poly(ADP-ribose) synthetase•IL 1, IL-6 ,IL11, IL-15, cyclooxygenase-2•c-jun, c-myc, elk-1•Oxidative stress genes, ApoJ, Hsp70, Heme oxygenase 2, SOD •Enoyl coA hydratase, PPAR , Acyl coA oxidase•C/EBP, IB-, NFB, erk-1, p38, HGF, TGFB RII•albumin, transferrin•CYP P450s (22), FMO, EH, MAO•GST (4), UGT(10), SULT(4)•MDR1, MRP (6), BSEP, OATP (4), OAT (2), OCT (2)•CAR, PXR, RXR, GR
175 human genes involved in drug metabolism at the hepatic level
![Page 19: NON CLINICAL DEVELOPMENT OF DRUG SPECIALITIES ________________________ Bernard MARCHAND](https://reader034.fdocuments.in/reader034/viewer/2022042617/56814a9a550346895db7aa04/html5/thumbnails/19.jpg)
HANDLING THE DATA
Databases for correct data use, the new challenge for tomorrow ?
Tools for rapid assessment of metabolism are available but how we handle the data has not yet been completely mastered
Data base
Log K ’CalculatedLogP, Rate of metabolism
Solubility, LogP Caco-2 Papp Microsomal Km/Vm IC50 inhibition n-in-one dosing CYP450 Km, Vm Ki
inhibition constant induction potential
n-in-one dosing
in Man ?Sorting molecules with Warnings and Metabolic SAR Sorting molecules
with in vivo scaled up data and Metabolic QSAR
Sorting molecules with partial or
total rebuilding of the entire population
Theoretical approach
HTS SDS
Preclinicaldevelopmen
t
1st administration to Man
Back up
![Page 20: NON CLINICAL DEVELOPMENT OF DRUG SPECIALITIES ________________________ Bernard MARCHAND](https://reader034.fdocuments.in/reader034/viewer/2022042617/56814a9a550346895db7aa04/html5/thumbnails/20.jpg)
PRECLINICAL STUDYPRECLINICAL STUDY PROGRAMMEPROGRAMME
Stage BStage A4 months4 months 6 6 monthsmonths
-Dose Ranging (3-7d) Rat + Non-Rodt- Ames test- Mouse Lymph.
-Drug Subst. Analyt. Chem.- Degradation
- 4 wk Tox Rat + Non-Rodt- Acute studies Rat + Mouse PO & IP or IV- Rat Bone Marrow micronucleus
- Choice of Salt- Tablet Formul. + Stability
- Assay Validation- Plasma Stability- TK 4 wk Rat- TK 4 wk Non-Rodt- TK Micronucleus- Def. PK Non-Rodt- Induct. Potential Rat + Non-Rdt* * if Rat positive - Enzymes identif. (human)- Intersp. Comp. 14C- Label. Cpd
- Assay developt- TK DoseRanging Rat+ Non-Rodt- PK Rat - Prel. PK Non-Rodt- Blood/Pl.Ratio- Prel. Metab. in vivo Rat- Prel. Prot. Bind. - Inhib. Potential- Intersp. Comp.- Feasibility label. cpd
200 g200 g 2.5 kg2.5 kg
![Page 21: NON CLINICAL DEVELOPMENT OF DRUG SPECIALITIES ________________________ Bernard MARCHAND](https://reader034.fdocuments.in/reader034/viewer/2022042617/56814a9a550346895db7aa04/html5/thumbnails/21.jpg)
Regulatory Toxicology – Early Programme #
Phase I requirements *Single dose toxicityRepeat dose toxicity studiesGenotoxicity studiesReproductive toxicity studies
* Other requirementsPharmacology (actions relevant to the proposed route)Safety pharmacologyPharmacokinetics (preliminary studies on absorption, distribution, metabolism and excretion) and in vitro metabolism studies
## ICH M3 : Nonclinical Safety Studies ICH M3 : Nonclinical Safety Studies
![Page 22: NON CLINICAL DEVELOPMENT OF DRUG SPECIALITIES ________________________ Bernard MARCHAND](https://reader034.fdocuments.in/reader034/viewer/2022042617/56814a9a550346895db7aa04/html5/thumbnails/22.jpg)
Regulatory Toxicology – Later Programme #
Phase II, III marketing application requirements *Chronic dose toxicity studiesCarcinogenicity studiesReproductive toxicity studiesAppropriate toxicity/genotoxicity studies on metabolites,impurities and/or excipient
* Other requirementsAdditional safety pharmacology (if necessary)Additional genotoxicity studies (if necessary)Phamacokinetics (studies on absorption, distribution, metabolism and excretion)
## ICH M3 : Nonclinical Safety Studies ICH M3 : Nonclinical Safety Studies
![Page 23: NON CLINICAL DEVELOPMENT OF DRUG SPECIALITIES ________________________ Bernard MARCHAND](https://reader034.fdocuments.in/reader034/viewer/2022042617/56814a9a550346895db7aa04/html5/thumbnails/23.jpg)
Duration of Toxicity Studies #
* NOTE in US and EU, as an alternative to repeat dose studies, single dose toxicity studies with extended examinations may support single dose human trials
Minimum duration of toxicityDuration of clinical trials Rodent Non –rodentSingle dose 2 weeks* 2 weeksUp to 2 weeks 2-4 weeks* 2 weeksUp to one month one month one monthUp to 3 months 3 months 3 monthsUp to 6 months 6 months 6 months - 1year> 6 months 6 months 1 year
To support phase I and II trials in EU and phase I, II and III trials
## ICH M3 : Nonclinical Safety Studies ICH M3 : Nonclinical Safety Studies
![Page 24: NON CLINICAL DEVELOPMENT OF DRUG SPECIALITIES ________________________ Bernard MARCHAND](https://reader034.fdocuments.in/reader034/viewer/2022042617/56814a9a550346895db7aa04/html5/thumbnails/24.jpg)
The battery can be completed with additional test(s) when necessary.Should permit to discard at the beginning of development potential genotoxic carcinogen compounds
AMES TEST: detection of reverse mutation on
S. typhimurium and E. coli (= procaryotes) MOUSE LYMPHOMA : detection of forward
mutation on cell lineage (= eucaryotes)can also detect clastogenic effects
IN V
ITRO
IN V
ITRO
IN V
IVO
IN V
IVO
MICRONUCLEUS on rat bone marrow: detection of chromosome breaks = clastogenicity
PRECLINICAL STUDIES
GENOTOXICITY : Standard Test Battery
![Page 25: NON CLINICAL DEVELOPMENT OF DRUG SPECIALITIES ________________________ Bernard MARCHAND](https://reader034.fdocuments.in/reader034/viewer/2022042617/56814a9a550346895db7aa04/html5/thumbnails/25.jpg)
- ACUTE :Route: intended for human -If oral route for human : ORAL + PARENTERAL (IV or IP)Species: MOUSE and RATExaminations :
MORTALITY CLINICAL SIGNS/ BEHAVIOR
GROSS OBSERVATION AT NECROPSY (Histopathology for gross lesions)
Acute toxicology profileMNLD = Maximal non-lethal
dose MLD = Minimal lethal dose
PRECLINICAL STUDIES
GENERAL TOXICOLOGY
![Page 26: NON CLINICAL DEVELOPMENT OF DRUG SPECIALITIES ________________________ Bernard MARCHAND](https://reader034.fdocuments.in/reader034/viewer/2022042617/56814a9a550346895db7aa04/html5/thumbnails/26.jpg)
- SUBCHRONIC and CHRONICRoute : intended for human Species : Rodent = RAT
Non-Rodent = DOG or MONKEYDosing : daily (or twice daily), 3 doses + controlDuration : up to 6 months (rodents)
9 to 12 months (non-rodents)Investigations : pluridisciplinary contributions
Define NOEL : No Effect Level orNOAEL: No Adverse Effect LevelTARGET ORGANS - BIOMARKERS
PRECLINICAL STUDIESGENERAL TOXICOLOGY
![Page 27: NON CLINICAL DEVELOPMENT OF DRUG SPECIALITIES ________________________ Bernard MARCHAND](https://reader034.fdocuments.in/reader034/viewer/2022042617/56814a9a550346895db7aa04/html5/thumbnails/27.jpg)
Clinical observationsbehavior
Toxicokinetic/Metabolism (enzyme induction/inhibition)
BodyweightFood/Water intakes
Necropsy Gross observations
40 organs/tissue samplesHistology process
Histopathology Electronmicroscopy
Urinalysis
BloodHematologyred, white cells andplatelet countsBiochemistry20 to 25 parameters
STANDARD TOXICOLOGY EVALUATIONS
![Page 28: NON CLINICAL DEVELOPMENT OF DRUG SPECIALITIES ________________________ Bernard MARCHAND](https://reader034.fdocuments.in/reader034/viewer/2022042617/56814a9a550346895db7aa04/html5/thumbnails/28.jpg)
- EMBRYOFETAL TOXICOLOGY :Hysterectomy
- uterus content: implantations, resorptions…
- external- visceral examinations of fetus- skeletal
Teratogenic effect?
- FERTILITY : Reproductive performanceMale : sperm analysis
+ histopathology of gonads
and accessory glandsFemale : oestrus cycle
PRECLINICAL STUDIES
REPRODUCTIVE TOXICOLOGY
![Page 29: NON CLINICAL DEVELOPMENT OF DRUG SPECIALITIES ________________________ Bernard MARCHAND](https://reader034.fdocuments.in/reader034/viewer/2022042617/56814a9a550346895db7aa04/html5/thumbnails/29.jpg)
- PERI-and POSTNATAL TOXICOLOGYParturitionLactationPhysical, sensory and behavioral development of pupsSecond generation study
Species : Rodent = RAT + Non Rodent = RABBIT (Lagomorph)
for embryofetal studies
PRECLINICAL STUDIES
REPRODUCTIVE TOXICOLOGY (contld)
![Page 30: NON CLINICAL DEVELOPMENT OF DRUG SPECIALITIES ________________________ Bernard MARCHAND](https://reader034.fdocuments.in/reader034/viewer/2022042617/56814a9a550346895db7aa04/html5/thumbnails/30.jpg)
These studies remain necessary to detect non-genotoxic carcinogens.Two species: RAT and MOUSETwo-year duration: LIFE SPAN for these speciesInvestigations :. Clinical observations and mortality. Feed and water intakes. Palpations: for detection of masses (subcutaneous, mammary glands,…). Necropsy
gross observationsorgan weightshistomorphologic evaluations 40 tissues or organs + masses
. Statistical analysis Conclusion about carcinogenic potential
PRECLINICAL STUDIESCARCINOGENESIS
![Page 31: NON CLINICAL DEVELOPMENT OF DRUG SPECIALITIES ________________________ Bernard MARCHAND](https://reader034.fdocuments.in/reader034/viewer/2022042617/56814a9a550346895db7aa04/html5/thumbnails/31.jpg)
PlasmaConcentration
1000
100
10
0 1 2 3 45
Time (h)
Toxicity treshold
Peak effect
Toxic effectsToxicokinetic
s
Pharmacologic effects Pharmacokinetic
s
TOXICOLOGY
![Page 32: NON CLINICAL DEVELOPMENT OF DRUG SPECIALITIES ________________________ Bernard MARCHAND](https://reader034.fdocuments.in/reader034/viewer/2022042617/56814a9a550346895db7aa04/html5/thumbnails/32.jpg)
Toxicological Requirement
Depending on toxicity, a frequently used “safety margin” for volunteer studies is 10 fold between dose which produces toxicity in animals and dose given to humans
First dose can be 1/100 of NOAEL
Final dose can be 1/10 of NOAEL
Plasma data on drug will give levels at which toxic effects may be expected and so must not be exceeded
Awareness that animal data not necessarily predict clinical toxicity
![Page 33: NON CLINICAL DEVELOPMENT OF DRUG SPECIALITIES ________________________ Bernard MARCHAND](https://reader034.fdocuments.in/reader034/viewer/2022042617/56814a9a550346895db7aa04/html5/thumbnails/33.jpg)
PRECLINICAL STUDYPRECLINICAL STUDY PROGRAMMEPROGRAMME
Pre- ProjectPre- Project
Stage BStage A
4 months4 months 6 months6 months 2 months2 months1 month1 month
Decision PointPreclinical Research
- Dose Ranging (3-7d) Rat + Non-Rodt- Ames test- Mouse Lymph.
- Drug Subst. Analyt. Chem.- Degradation
- 4 wk Tox Rat + Non-Rodt- Acute studies Rat + Mouse PO & IP or IV- Rat Bone Marrow micronucleus
- Choice of Salt- Tablet Formul. + Stability
- Assay Validation- Plasma Stability- TK 4 wk Rat- TK 4 wk Non-Rodt- TK Micronucleus- Def. PK Non-Rodt- Induct. Potential Rat + Non-Rdt* * if Rat positive - Enzymes identif. (human)- Intersp. Comp. 14C- Label. Cpd
Check List
Preclinical SummaryBoard Committee
Development Decision
- Production clinical batch Phase I (capsule)
Investigator brochure
- Clinical Assay- Plasma Stab. (man)- TK assay (transfer to CRO)- TK Dose Ranging ReproTox - WBA Rat- Mass Bal. Rat & in vivo Met. - Def. Prot. Bind. (label. cpd)
- Dose Ranging ReproTox
- Assay developt- TK DoseRanging Rat+ Non-Rodt- PK Rat - Prel. PK Non-Rodt- Blood/Pl.Ratio- Prel. Metab. in vivo Rat- Prel. Prot. Bind. - Inhib. Potential- Intersp. Comp.- Feasibility label. cpd
16 kg16 kg200 g200 g 2.5 kg2.5 kg
IMPD
![Page 34: NON CLINICAL DEVELOPMENT OF DRUG SPECIALITIES ________________________ Bernard MARCHAND](https://reader034.fdocuments.in/reader034/viewer/2022042617/56814a9a550346895db7aa04/html5/thumbnails/34.jpg)
PHASE 1 STUDIES
Clinical PharmacokineticsClinical PharmacokineticsPhase I : dose Phase I : dose tolerancetolerance
0 6 12 18 24
Time (h)
1
10
100
1000
10000
Conc
entra
tion
0
5
10
15
20
0 30 60 90 120
Dose
AU
C
Dosing 600-900 samples in real time
![Page 35: NON CLINICAL DEVELOPMENT OF DRUG SPECIALITIES ________________________ Bernard MARCHAND](https://reader034.fdocuments.in/reader034/viewer/2022042617/56814a9a550346895db7aa04/html5/thumbnails/35.jpg)
TARGETORGANS
(TISSUES)
GASTRO INTESTINAL TRACT
BLOOD CIRCULATION
First pass effect
Portal vein
LIVER
1
10
100
1000
0 4 8 12 16 20 24Time (h)
Con
cent
ratio
n
ABSORPTION
DISTRIBUTION
Cmax
tmax
+ ELIMINATION
Administration
EXCRETION
Bile
AUC Exposure
ORAL ROUTEORAL ROUTE
SINGLE DOSE PK
![Page 36: NON CLINICAL DEVELOPMENT OF DRUG SPECIALITIES ________________________ Bernard MARCHAND](https://reader034.fdocuments.in/reader034/viewer/2022042617/56814a9a550346895db7aa04/html5/thumbnails/36.jpg)
1
10
100
1000
0 4 8 12 16 20 24Time (h)
Con
cent
ratio
n
1
10
100
1000
0 4 8 12 16 20 24
Time (h)
Con
cent
ratio
n
Integration of physiological parameters and in vitro measurements
Qtissues
Qmuscles
Q portal v.
Q hepatic. a
Qheart
Kp liver
Vmax Km fabs
Kpheart
Kplung
Kptissues
Kpmuscles
![Page 37: NON CLINICAL DEVELOPMENT OF DRUG SPECIALITIES ________________________ Bernard MARCHAND](https://reader034.fdocuments.in/reader034/viewer/2022042617/56814a9a550346895db7aa04/html5/thumbnails/37.jpg)
BioavailabilityInter/intra
subjectvariabilit
y
Drug-drug interaction
Intestinal absorptionMetabolic stabilityMetabolic pathwaysP450 Isoenzymes Inhibition potentialInduction potentialPrediction of the main
drug characteristics with respect to the entire population
Rebuild (predict) of the in vivo situation
Evaluation of simple drug metabolism
parameters
DMPK ISSUES IN DRUG DEVELOPMENT
![Page 38: NON CLINICAL DEVELOPMENT OF DRUG SPECIALITIES ________________________ Bernard MARCHAND](https://reader034.fdocuments.in/reader034/viewer/2022042617/56814a9a550346895db7aa04/html5/thumbnails/38.jpg)
PREDICTIONS IN VIVO Interindividual variability
CYP1A1 CYP1A2CYP1A1 CYP1A2CYP2C9CYP2C9
Extreme subjects of
the simulation
Time (h)Time (h)
Con
cent
ratio
n (µ
M)
Con
cent
ratio
n (µ
M)
![Page 39: NON CLINICAL DEVELOPMENT OF DRUG SPECIALITIES ________________________ Bernard MARCHAND](https://reader034.fdocuments.in/reader034/viewer/2022042617/56814a9a550346895db7aa04/html5/thumbnails/39.jpg)
IN VIVO PREDICTIONSIN VIVO PREDICTIONSDrug-drug interactionsDrug-drug interactions
1
10
100
1000
Con
cent
ratio
n
0 4 8 12 16 20 24
Time (h)
+ inductor
+ inhibitor
+
+
![Page 40: NON CLINICAL DEVELOPMENT OF DRUG SPECIALITIES ________________________ Bernard MARCHAND](https://reader034.fdocuments.in/reader034/viewer/2022042617/56814a9a550346895db7aa04/html5/thumbnails/40.jpg)
PHASE II PK/PD
0
50
100
150
200
0 50 100 150 200 250 300 350 400 450
concentrationEf
fect
0200400600800
100012001400160018002000
0 0.5 1 1.5 2 2.5 3 3.5 4 4.5 5 5.5 60
10
20
30
40
50
60
70
80
Effect
Cp
Ce
Direct Direct effecteffectEffectEffect versus Cpversus Cp
Delayed effectDelayed effectEffect versus Ce
PharmacokineticPharmacokinetic / / Pharmacodynamic AnalysisPharmacodynamic Analysis
0
100
200
300
400
500
600
700
0 0.5 1 1.5 2 2.5 3 3.5 4 4.5 5 5.5 60
20
40
60
80
100
120
140
Effect
Plasmaconcentration
Cp
![Page 41: NON CLINICAL DEVELOPMENT OF DRUG SPECIALITIES ________________________ Bernard MARCHAND](https://reader034.fdocuments.in/reader034/viewer/2022042617/56814a9a550346895db7aa04/html5/thumbnails/41.jpg)
Simulations
Dissolution model :Relationship between In vitro and In vivo dissolution
PK/PD model :Relationship between plasma concentrations and effects
Pharmacodynamicobjectives
Sustained releaseformulation
Why a modelling approach?
A clinical studyper formulation
PK model : Absorption, distribution, elimination
![Page 42: NON CLINICAL DEVELOPMENT OF DRUG SPECIALITIES ________________________ Bernard MARCHAND](https://reader034.fdocuments.in/reader034/viewer/2022042617/56814a9a550346895db7aa04/html5/thumbnails/42.jpg)
FORMULATION RESEARCH
Oral RouteOral RouteTablets and CapsulesFast Dissolving Forms
Slow Release FormulationDelayed Formulation
Injectable RouteInjectable RouteBolus and Infusion
Slow Release Formulation
Transdermal RouteTransdermal RoutePatches
Iontophoresis devices
Transmucosal RouteTransmucosal RouteBuccalNasal
Pulmonary
![Page 43: NON CLINICAL DEVELOPMENT OF DRUG SPECIALITIES ________________________ Bernard MARCHAND](https://reader034.fdocuments.in/reader034/viewer/2022042617/56814a9a550346895db7aa04/html5/thumbnails/43.jpg)
ORAL ROUTE/PROLONGED RELEASEHYDROPHILIC MATRIX
Gastro intestinal fluids penetrate the polymer layer which, consequently, swells and forms a gel which controls the release kinetics of the drug substance
H2O
HPMC
![Page 44: NON CLINICAL DEVELOPMENT OF DRUG SPECIALITIES ________________________ Bernard MARCHAND](https://reader034.fdocuments.in/reader034/viewer/2022042617/56814a9a550346895db7aa04/html5/thumbnails/44.jpg)
ORAL ROUTE / HYDROPHILIC MATRIX
In vitro dissolution profile
0
50
100
0 4 8 12 16
Prolonged Release
Immediate Release
%
H
![Page 45: NON CLINICAL DEVELOPMENT OF DRUG SPECIALITIES ________________________ Bernard MARCHAND](https://reader034.fdocuments.in/reader034/viewer/2022042617/56814a9a550346895db7aa04/html5/thumbnails/45.jpg)
ORAL ROUTE / HYDROPHILIC MATRIX
0
20
40
60
80
0 24 48 72
Immediate Release
Prolonged Release
[ng/ml]
H
In Vivo
![Page 46: NON CLINICAL DEVELOPMENT OF DRUG SPECIALITIES ________________________ Bernard MARCHAND](https://reader034.fdocuments.in/reader034/viewer/2022042617/56814a9a550346895db7aa04/html5/thumbnails/46.jpg)
ORAL ROUTE / PROLONGED RELEASESEMI SOLID LIPOPHILIC MATRIX
• Control of the release kinetics is obtained by the choice of the excipient and by its hydrophilic-lipophilic balance (HLB).
• Manufacturing process, excipient melting, drug substance dispersion in the molten mass and, pouring into hard gelatin capsules
![Page 47: NON CLINICAL DEVELOPMENT OF DRUG SPECIALITIES ________________________ Bernard MARCHAND](https://reader034.fdocuments.in/reader034/viewer/2022042617/56814a9a550346895db7aa04/html5/thumbnails/47.jpg)
ORAL ROUTESEMI SOLID MATRIX STABILISATION
Figure 5
Antiparkinson drug - 30°C/60%HRWithout stabilisation
0
25
50
75
100
0 4 8 12 16
Time (h)
Dru
g Su
bsta
nce
diss
olve
d, %
initial1 month2 months3 months
Antiparkinson drug - 30°C/60%HRWith stabilisation (Servier's patent)
0
25
50
75
100
0 4 8 12 16
Time (h)
Dru
g Su
bsta
nce
diss
olve
d, %
initial1 month2 months3 months
![Page 48: NON CLINICAL DEVELOPMENT OF DRUG SPECIALITIES ________________________ Bernard MARCHAND](https://reader034.fdocuments.in/reader034/viewer/2022042617/56814a9a550346895db7aa04/html5/thumbnails/48.jpg)
• Multiparticulate dosage form as small spherical reservoir beads (0.5 à1.5 mm diameter)
• Dissolution rate controlled by a semi-permeable membrane
ORAL ROUTE / PROLONGED RELEASEMICROPARTICLES
![Page 49: NON CLINICAL DEVELOPMENT OF DRUG SPECIALITIES ________________________ Bernard MARCHAND](https://reader034.fdocuments.in/reader034/viewer/2022042617/56814a9a550346895db7aa04/html5/thumbnails/49.jpg)
PROLONGED RELEASE MICROPARTICLES
Filters
Coating solution
Hot air
Semi permeable membraneDrug substance +
Excipients
![Page 50: NON CLINICAL DEVELOPMENT OF DRUG SPECIALITIES ________________________ Bernard MARCHAND](https://reader034.fdocuments.in/reader034/viewer/2022042617/56814a9a550346895db7aa04/html5/thumbnails/50.jpg)
In vitro dissolution rate of two different dosage forms
0
25
50
75
100
0 4 8 12 16 20 24
Time (h)
Dru
g Su
bsta
nce
diss
olve
d, %
Steady-state plasma concentrations of the two different dosage forms
0102030405060708090
72 78 84 90 96 102
Time (h)
Plas
ma
conc
entr
atio
n (n
g/m
l)
ORAL ROUTESUSTAINED RELEASE MICROPARTICLES
IRIR
PPRR
IR 3 x dayIR 3 x day
PR 1 x dayPR 1 x day
![Page 51: NON CLINICAL DEVELOPMENT OF DRUG SPECIALITIES ________________________ Bernard MARCHAND](https://reader034.fdocuments.in/reader034/viewer/2022042617/56814a9a550346895db7aa04/html5/thumbnails/51.jpg)
ORAL ROUTE / DELAYED RELEASE
0
20
40
60
80
100
120
0 2 4 6 8 10 12 14 16 18Time (h)Time (h)
Drug Drug substance substance released (%)released (%)
![Page 52: NON CLINICAL DEVELOPMENT OF DRUG SPECIALITIES ________________________ Bernard MARCHAND](https://reader034.fdocuments.in/reader034/viewer/2022042617/56814a9a550346895db7aa04/html5/thumbnails/52.jpg)
ORAL ROUTE / DELAYED RELEASE
012345678
0 2 4 6 8 10 12 16 20 24 Time (h)
plasma concentration
(ng/ml)IR
DR
![Page 53: NON CLINICAL DEVELOPMENT OF DRUG SPECIALITIES ________________________ Bernard MARCHAND](https://reader034.fdocuments.in/reader034/viewer/2022042617/56814a9a550346895db7aa04/html5/thumbnails/53.jpg)
0
4
8
12
0 4 8 12 16 20 24Time (h)
ng/ml
ORAL ROUTE DELAYED AND PROLONGED RELEASE MICROPARTICLES
Plasma Concentration
In vitro dissolution rate
0
50
100
0 4 8 12 16Time (h)D
rug
subs
tanc
e re
leas
ed
(%)
![Page 54: NON CLINICAL DEVELOPMENT OF DRUG SPECIALITIES ________________________ Bernard MARCHAND](https://reader034.fdocuments.in/reader034/viewer/2022042617/56814a9a550346895db7aa04/html5/thumbnails/54.jpg)
ExploExplo
ProjecProjectt
Preclinical Preclinical Stage AStage A Phase IPhase I Phase Phase
IIII
Phase IIIPhase III NDANDAPost Post NDANDA
Preclinical Preclinical Stage BStage B
BioPharmaceutica
l Research
TOXICOADME
Salt Selection
Phase IFormulatio
n
PK Interaction
sPB/PK
PK/PD
Up scaled Formulatio
n
Toxicological and kinetics Expertises
PopulationKinetic
Interspecies
metabolismcomparison
Pharmaceutical File
NewFormulation
Pharmaceutical
Support Regulatory
AffairsPharmacopoe
iaCopy
Analysis
![Page 55: NON CLINICAL DEVELOPMENT OF DRUG SPECIALITIES ________________________ Bernard MARCHAND](https://reader034.fdocuments.in/reader034/viewer/2022042617/56814a9a550346895db7aa04/html5/thumbnails/55.jpg)
POPULATION KINETIC
Time
Plas
ma
conc
entra
tion
CL creat
CL
renal impaired subjects
healthy subjects
Time
Plas
ma
conc
entra
tion
Bayesian feedback
PopulationPopulation Analysis Analysis
Time
plas
ma
conc
entr
atio
n
Population simulations((variabilityvariability))
![Page 56: NON CLINICAL DEVELOPMENT OF DRUG SPECIALITIES ________________________ Bernard MARCHAND](https://reader034.fdocuments.in/reader034/viewer/2022042617/56814a9a550346895db7aa04/html5/thumbnails/56.jpg)
12
34
56
78
9
C L c r (L / h )1 82 83 84 85 86 87 88 89 8
A g e (Y e a r s )
C L / F (L / h )
247
1 01 31 61 92 12 42 73 03 33 63 94 1
C l e a r a n c e E x t r a p o l a t i o nC l e a r a n c e E x t r a p o l a t i o n
![Page 57: NON CLINICAL DEVELOPMENT OF DRUG SPECIALITIES ________________________ Bernard MARCHAND](https://reader034.fdocuments.in/reader034/viewer/2022042617/56814a9a550346895db7aa04/html5/thumbnails/57.jpg)
• Therapeutic windowTherapeutic window• Relation conc. / effectsRelation conc. / effects• Side effectsSide effects• ToxicityToxicity• etc.etc.
• AbsorptionAbsorption• DistributionDistribution• MetabolismMetabolism• EliminationElimination• etc.etc.
• Status of the patient Status of the patient • Age, weightAge, weight• Stage of the illnessStage of the illness• Associated pathologiesAssociated pathologies• Associated treatmentsAssociated treatments• ComplianceCompliance• etc.etc.
• Administration routesAdministration routes• FormulationFormulation• Tolerance - addictionTolerance - addiction• Drug interactionsDrug interactions• Genetic Genetic PolymorphismPolymorphism• etc.etc.
Clinical Factors
Pharmacokinetics
OtherFactors
Activity - Toxicity
Clinical PKcs
Regimen
![Page 58: NON CLINICAL DEVELOPMENT OF DRUG SPECIALITIES ________________________ Bernard MARCHAND](https://reader034.fdocuments.in/reader034/viewer/2022042617/56814a9a550346895db7aa04/html5/thumbnails/58.jpg)
ExploExplo
ProjecProjectt
Preclinical Preclinical Stage AStage A Phase IPhase I Phase Phase
IIII
Phase IIIPhase III NDANDAPost Post NDANDA
Preclinical Preclinical Stage BStage B
BioPharmaceutica
l Research
TOXICOADME
Salt Selection
Phase IFormulatio
n
PK Interaction
sPB/PK
PK/PD
Up scaled Formulatio
n
Toxicological and kinetics Expertises
PopulationKinetic
Interspecies
metabolismcomparison
Pharmaceutical File
NewFormulation
Pharmaceutical
Support Regulatory
AffairsPharmacopoe
iaCopy
Analysis
![Page 59: NON CLINICAL DEVELOPMENT OF DRUG SPECIALITIES ________________________ Bernard MARCHAND](https://reader034.fdocuments.in/reader034/viewer/2022042617/56814a9a550346895db7aa04/html5/thumbnails/59.jpg)
Pharmaceutical FilePharmaceutical File
COHERENCEAnalytical Methods
Impurities Degradation products
FORMULATION DESCRIPTIONDiluting and lubrification agents
Added excipients
REGULATORYCONSTRAINTS
% Qualification
![Page 60: NON CLINICAL DEVELOPMENT OF DRUG SPECIALITIES ________________________ Bernard MARCHAND](https://reader034.fdocuments.in/reader034/viewer/2022042617/56814a9a550346895db7aa04/html5/thumbnails/60.jpg)
PHARMACEUTICAL DEVELOPMENT
2 Definitions :
Drug substance = Active substance (New Chemical Entity or existing drug substance )
Drug product = medicinal product = Finished product (tablets, capsules, …)
![Page 61: NON CLINICAL DEVELOPMENT OF DRUG SPECIALITIES ________________________ Bernard MARCHAND](https://reader034.fdocuments.in/reader034/viewer/2022042617/56814a9a550346895db7aa04/html5/thumbnails/61.jpg)
BEGINNING OF PHARMACEUTICAL DEVELOPMENT (1)
Physicochemical properties of the new drug substance
solubility in water at different pH valueskinetics of dissolution as a function of
particle size........
Stability of the drug substance itselfstress conditions (acidic or basic pH, oxidation, temperature)
![Page 62: NON CLINICAL DEVELOPMENT OF DRUG SPECIALITIES ________________________ Bernard MARCHAND](https://reader034.fdocuments.in/reader034/viewer/2022042617/56814a9a550346895db7aa04/html5/thumbnails/62.jpg)
BEGINNING OF PHARMACEUTICAL DEVELOPMENT (2)
Choice of salt and cristalin form for development
- Solubility- Stability
Chemical compatibility drug substance/excipients
Formulations for phase I
![Page 63: NON CLINICAL DEVELOPMENT OF DRUG SPECIALITIES ________________________ Bernard MARCHAND](https://reader034.fdocuments.in/reader034/viewer/2022042617/56814a9a550346895db7aa04/html5/thumbnails/63.jpg)
TYPES OF FORMULATION / ORAL ROUTE
Release of the drug substance
Immediate release (IR)
Modified release (MR)
prolonged release delayed release
![Page 64: NON CLINICAL DEVELOPMENT OF DRUG SPECIALITIES ________________________ Bernard MARCHAND](https://reader034.fdocuments.in/reader034/viewer/2022042617/56814a9a550346895db7aa04/html5/thumbnails/64.jpg)
IMMEDIATE RELEASE TABLET
Drug substance
Diluant (lactose, mannitol ....)
Binder (povidone,HPMC, maltodextrin ....)
Desintegrating agent (sodium starch glycolate,…)
Flowing agent (silica, talc ....)
Lubricant (magnesium stearate, stearic acid ....)
![Page 65: NON CLINICAL DEVELOPMENT OF DRUG SPECIALITIES ________________________ Bernard MARCHAND](https://reader034.fdocuments.in/reader034/viewer/2022042617/56814a9a550346895db7aa04/html5/thumbnails/65.jpg)
THE IDEAL FORMULATION (1)
Easy to manufacture, with a robust process giving always a quality product
Delivering the drug substance as needed according to its intrinsec pharmacokinetic properties (half-life, site of absorption......) and to the therapeutic needs :
prolonged release for a once-a-day formulation of a drug substance with a short half-life
quick Cmax to get an effect quickly lower Cmax to decrease side effects ......
Stable throughout the storage period chemical stability of the drug no evolution of the dissolution profile
![Page 66: NON CLINICAL DEVELOPMENT OF DRUG SPECIALITIES ________________________ Bernard MARCHAND](https://reader034.fdocuments.in/reader034/viewer/2022042617/56814a9a550346895db7aa04/html5/thumbnails/66.jpg)
INTERNATIONAL CONFERENCE OF HARMONISATION : I.C.H. PROCESS
Since 1990
The aim: to standardize the studies to be performed for the registration of a new product in the 3 main geographical areas :
• USA/Canada• Japon• European Union
3 topics• Safety (guidelines S) / Toxicology• Efficacy (guidelines E) / Clinical development• Quality (guidelines Q) / Pharmaceutical
development
![Page 67: NON CLINICAL DEVELOPMENT OF DRUG SPECIALITIES ________________________ Bernard MARCHAND](https://reader034.fdocuments.in/reader034/viewer/2022042617/56814a9a550346895db7aa04/html5/thumbnails/67.jpg)
I.C.H. PROCESSExample : Stability for zone II
Drug substance : 3 batches packaging representative of industrial packaging
Drug product : 3 batches (the size of 2 out of 3 is more than 1/10
that of industrial batches) packaging chosen for the market
Conditions : 25°C/60%RH throughout shelf-life 30°C/60%RH (65%RH in 2005) 1 year 40°C/75%RH 6 months
Time of analysis : 0, 3 months, 6 months, 9 months, 1 year,
18 months, 2 years, 3 years
![Page 68: NON CLINICAL DEVELOPMENT OF DRUG SPECIALITIES ________________________ Bernard MARCHAND](https://reader034.fdocuments.in/reader034/viewer/2022042617/56814a9a550346895db7aa04/html5/thumbnails/68.jpg)
MARKETING AUTHORISATION FILEDRUG SUBSTANCE
S.2 Preparation/synthesis
S.3 Characterisation (Physico-chemical properties,
structure and qualification of impurities)
S.4 Control of drug substance
S.7 Stability
![Page 69: NON CLINICAL DEVELOPMENT OF DRUG SPECIALITIES ________________________ Bernard MARCHAND](https://reader034.fdocuments.in/reader034/viewer/2022042617/56814a9a550346895db7aa04/html5/thumbnails/69.jpg)
MARKETING AUTHORISATION FILE DRUG PRODUCT
P.1 Description and composition
P.2 Process development/validation
P.3 Manufacturing process
P.4 Excipients
P.5 Control of drug product
P.7 Container closure system
P.8 Stability shelf-life and storage conditions
![Page 70: NON CLINICAL DEVELOPMENT OF DRUG SPECIALITIES ________________________ Bernard MARCHAND](https://reader034.fdocuments.in/reader034/viewer/2022042617/56814a9a550346895db7aa04/html5/thumbnails/70.jpg)
Change in Production SiteChange in Production Site
Improvment Improvment of of
Analytical Analytical TechnicsTechnics
StabilityStability New SpecificationsNew Specifications SolvantsSolvants
ImpuritiesImpurities
Up dating of the CMC File
![Page 71: NON CLINICAL DEVELOPMENT OF DRUG SPECIALITIES ________________________ Bernard MARCHAND](https://reader034.fdocuments.in/reader034/viewer/2022042617/56814a9a550346895db7aa04/html5/thumbnails/71.jpg)
PHARMACOPEAPHARMACOPEA
1st WAY
SETTING THE SPECIFICATION OF THE ACTIVE PRINCIPLE
2nd WAY
Consensus within competitors Before patent issueMonopole situation
![Page 72: NON CLINICAL DEVELOPMENT OF DRUG SPECIALITIES ________________________ Bernard MARCHAND](https://reader034.fdocuments.in/reader034/viewer/2022042617/56814a9a550346895db7aa04/html5/thumbnails/72.jpg)
PHARMACOPEA FOR PERINDOPRIL
STRUCTURE Isomere S S S S S 31 isomeres as potentialimpurities < 0.1 %
TRACING IMPURITY
N
CO - CH - NH - CH - C3H7
COOH(7a)
(3a)
(2)
(9) (11)
CH3 COOC2H5
N COOH
OCH3
NH
COOC2H5
H HC3H7
H
H
![Page 73: NON CLINICAL DEVELOPMENT OF DRUG SPECIALITIES ________________________ Bernard MARCHAND](https://reader034.fdocuments.in/reader034/viewer/2022042617/56814a9a550346895db7aa04/html5/thumbnails/73.jpg)
1st pathway : Standard analysis criteria :
purity profil dissolution content
2nd pathway : Qualitative and Quantitative Analysis of the Formulation
COPIES AND COUNTERFEITS
How to distinguish Real from False ?How to distinguish Real from False ?
![Page 74: NON CLINICAL DEVELOPMENT OF DRUG SPECIALITIES ________________________ Bernard MARCHAND](https://reader034.fdocuments.in/reader034/viewer/2022042617/56814a9a550346895db7aa04/html5/thumbnails/74.jpg)
Suspicion of counterfeited Servier drugAnalysis of a whole truck content official ceremony to distroy the unlegal product
EX : SUSPECTED DRUG
ChinaChina
IndonesiaIndonesiaSuspicion of counterfeit but appeared to be parallel import through Australia then ???... Indonesia
MalteMalteSuspicion of parallel import finally proved to be counterfeits
![Page 75: NON CLINICAL DEVELOPMENT OF DRUG SPECIALITIES ________________________ Bernard MARCHAND](https://reader034.fdocuments.in/reader034/viewer/2022042617/56814a9a550346895db7aa04/html5/thumbnails/75.jpg)
ExploExplo
ProjecProjectt
Preclinical Preclinical Stage AStage A Phase IPhase I Phase Phase
IIII
Phase IIIPhase III NDANDAPost Post NDANDA
Preclinical Preclinical Stage BStage B
BioPharmaceutica
l Research
TOXICOADME
Salt Selection
Phase IFormulatio
n
PK Interaction
sPB/PK
PK/PD
Up scaled Formulatio
n
Toxicological and kinetics Expertises
PopulationKinetic
Interspecies
metabolismcomparison
Pharmaceutical File
NewFormulation
Pharmaceutical
Support Regulatory
AffairsPharmacopoe
iaCopy
Analysis
![Page 76: NON CLINICAL DEVELOPMENT OF DRUG SPECIALITIES ________________________ Bernard MARCHAND](https://reader034.fdocuments.in/reader034/viewer/2022042617/56814a9a550346895db7aa04/html5/thumbnails/76.jpg)
PHARMACEUTICAL PHARMACEUTICAL DEVELOPMENTDEVELOPMENT
Staff : 150Analytical methodsStability & Purity
analysisFormulation
Drug Delivery
Orléans VignatOrléans Vignat
TOXICOLOGYTOXICOLOGYGidyGidy
Staff : 109General Toxicology
Reproductive ToxicologyMutagenesis
CancerogenesisDrug Safety Research Drug Safety Research
Center GidyCenter Gidy Orléans Bel AirOrléans Bel Air
PHARMACOKINETICSPHARMACOKINETICS
LondonLondon
OrléansOrléans Staff : 136 (3 sites)Screening
ADME studiesPK/PD RelationshipsPopulation kinetics
Wexham, LondonWexham, London
CourbevoiCourbevoiee
OrléansOrléans
CourbevoieCourbevoie
BIOPHARMACYBIOPHARMACY
![Page 77: NON CLINICAL DEVELOPMENT OF DRUG SPECIALITIES ________________________ Bernard MARCHAND](https://reader034.fdocuments.in/reader034/viewer/2022042617/56814a9a550346895db7aa04/html5/thumbnails/77.jpg)